# A-Alpha Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/a-alpha-bio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.aalphabio.com
- Total disclosed funding: $45M
- Latest round: Series A (Jul 25, 2023)
- Investors on record: 9

## About

Founded in 2017 and based in Washington, US, A-Alpha Bio, Inc. operates as a protein-protein interaction company. The company was founded by its CEO, David Younger, and CTO, Randolph Lopez. In June 2024, A-Alpha Bio, Inc. raised USD 14.5 million in venture funding from the Department of Defense.

A-Alpha Bio offers a drug discovery platform focused on understanding and manipulating protein interactions. The firm employs synthetic biology and machine learning to measure and predict these interactions. Their platform, AlphaSeq, generates extensive protein interaction data, while AlphaBind uses this data to create predictive models.

The company plans to use the funds raised in June 2024 to carry out a project with the national lab for any future biological threats.

## Funding rounds

- Series A, Jul 25, 2023, $22M — Madrona Venture Group, Breakout Ventures, Perceptive Advisors
- Series A, Aug 24, 2021, $20M — Madrona Venture Group, Lux Capital, Perceptive Advisors
- Seed, Sep 24, 2019, $2.8M — Madrona Venture Group, Washington Research Group, AME Cloud Ventures, Awaken Capital, Boom Capital Management, Sahsen Foundation

## Investors

- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Seed, Series A
- Washington Research Group — Seed
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Seed
- Awaken Capital (https://capitalatlas.ai/funds/awaken-capital) — Seed
- Boom Capital Management (https://capitalatlas.ai/funds/boom-capital-management) — Seed
- Sahsen Foundation — Seed
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A
- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Series A